Novartis

Dividends and taxation: the importance of tax-exempt dividends (3/3)

This post is part 3 of 3 in the series Tax-exempt dividends

The article explores the progressivity of taxation in Switzerland and its impact on income, while addressing the issue of dividends and their taxation. Through an original ice-cream metaphor, it illustrates the importance of investment choices and their consequences on tax returns.

Dividends and taxation: the importance of tax-exempt dividends (3/3) Read More »

Identifying quality Swiss stocks and promoting them (4/6)

This post is part 4 of 6 in the series Identifying quality Swiss stocks and promoting them

Discover the essential criteria for assessing dividend quality, including current rate, growth and payout ratio. An in-depth analysis of dividend stability and their importance in a long-term investment strategy, illustrated by real-world examples such as EMS Chemie and Schaffner.

Identifying quality Swiss stocks and promoting them (4/6) Read More »

Investing in Swiss real estate companies: a good idea for the dividend-oriented investor?

Swiss real estate companies currently offer particularly attractive dividend yields, even exceeding those of SMI giants such as Nestlé, Novartis or Roche. An analysis of the six largest real estate companies reveals attractive investment opportunities, although their payout ratios vary considerably and their performance is sensitive to interest rate fluctuations.

Investing in Swiss real estate companies: a good idea for the dividend-oriented investor? Read More »

SMI and growing dividends (by Jean-Louis – guest member)

Discover an in-depth analysis of Swiss SMI companies that offer attractive and regular dividends for investors. The article examines in detail the performance of large companies such as Nestlé, Roche, Swisscom and Syngenta, while assessing their reliability and potential for an investment strategy based on growing dividends.

SMI and growing dividends (by Jean-Louis – guest member) Read More »

Novartis (VTX:NOVN)

Discover the detailed analysis of Novartis, the pharmaceutical giant born from the merger of Ciba-Geigy and Sandoz, and its dividend policy that raises ethical and economic questions. Between job cuts and sustainable dividend growth, let's explore how this global leader in pharma balances its social responsibilities and financial performance.

Novartis (VTX:NOVN) Read More »